Best Practice & Research Clinical Gastroenterology
Volume 24, Issue 2 , Pages 193-201 , April 2010

Adverse effects of proton pump inhibitors

  • Francesca Lodato, MD

      Affiliations

    • Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy
    • Department of Internal Medicine, Ageing and Nephrological Diseases, University of Bologna, Bologna, Italy
    • Corresponding Author InformationCorresponding author. Dipartimento di Medicina Interna e Gastroenterologia, Policlinico Sant'Orsola-Malpighi, Via Massarenti 9, 40138 Bologna, Italy. Tel./fax: +39 051 6364120.
    • ,
  • Francesco Azzaroli, MD

      Affiliations

    • Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy
    • ,
  • Laura Turco, MD

      Affiliations

    • Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy
    • ,
  • Natalia Mazzella, MD

      Affiliations

    • Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy
    • ,
  • Federica Buonfiglioli, MD

      Affiliations

    • Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy
    • ,
  • Marco Zoli, MD

      Affiliations

    • Department of Internal Medicine, Ageing and Nephrological Diseases, University of Bologna, Bologna, Italy
    • ,
  • Giuseppe Mazzella, MD

      Affiliations

    • Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy

References 

  1. Bamberg P, Caswell CM, Frame MH, et al. A meta-analysis comparing the efficacy of omeprazole with H2-receptor antagonists for acute treatment of duodenal ulcer in Asian patients. J Gastroenterol Hepatol. 1992;7:577–585
  2. Eriksson S, Langstrom G, Rikner L, et al. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. Eur J Gastroenterol Hepatol. 1995;7:467–475
  3. Gisbert JP, Gonzalez L, Calvet X, et al. Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther. 2001;15:917–926
  4. Gisbert JP, Khorrami S, Calvet X, et al. Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists–their efficacy with antibiotics in Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003;18:757–766
  5. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:190–200
  6. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104:728–738
  7. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772–781
  8. Grube RR, May DB. Stress ulcer prophylaxis in hospitalized patients not in intensive care units. Am J Health Syst Pharm. 2007;64:1396–1400
  9. Sachs G, Shin JM, Briving C, et al. The pharmacology of the gastric acid pump: the H+, K+ ATPase. Annu Rev Pharmacol Toxicol. 1995;35:277–305
  10. Andersson T, Cederberg C, Edvardsson G, et al. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther. 1990;47:79–85
  11. Eggleston A, Wigerinck A, Huijghebaert S, et al. Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: a clinical database analysis. Gut. 1998;42:13–16
  12. Ofman JJ, Dorn GH, Fennerty MB, et al. The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002;16:261–273
  13. Boath EH, Blenkinsopp A. The rise and rise of proton pump inhibitor drugs: patients' perspectives. Soc Sci Med. 1997;45:1571–1579
  14. Lanzon-Miller S, Pounder RE, Hamilton MR, et al. Twenty-four-hour intragastric acidity and plasma gastrin concentration in healthy subjects and patients with duodenal or gastric ulcer, or pernicious anaemia. Aliment Pharmacol Ther. 1987;1:225–237
  15. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther. 1998;12:605–612
  16. Lamberts R, Creutzfeldt W, Struber HG, et al. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology. 1993;104:1356–1370
  17. Walsh JH. Role of gastrin as a trophic hormone. Digestion. 1990;47(Suppl. 1):11–16discussion 49–52
  18. Wolfe MM, Soll AH. The physiology of gastric acid secretion. N Engl J Med. 1988;319:1707–1715
  19. Mattsson H, Havu N, Brautigam J, et al. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlike-cell carcinoids in the rat. Gastroenterology. 1991;100:311–319
  20. Lee H, Hakanson R, Karlsson A, et al. Lansoprazole and omeprazole have similar effects on plasma gastrin levels, enterochromaffin-like cells, gastrin cells and somatostatin cells in the rat stomach. Digestion. 1992;51:125–132
  21. Borch K, Renvall H, Liedberg G. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology. 1985;88:638–648
  22. Bardram L, Thomsen P, Stadil F. Gastric endocrine cells in omeprazole-treated and untreated patients with the Zollinger–Ellison syndrome. Digestion. 1986;35(Suppl. 1):116–122
  23. Rindi G, Luinetti O, Cornaggia M, et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology. 1993;104:994–1006
  24. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology. 2000;118:661–669
  25. Solcia E, Rindi G, Havu N, et al. Qualitative studies of gastric endocrine cells in patients treated long-term with omeprazole. Scand J Gastroenterol Suppl. 1989;166:129–137discussion 138–9
  26. Solcia E, Fiocca R, Havu N, et al. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion. 1992;51(Suppl. 1):82–92
  27. Hakanson R, Larsson LI, Liedberg G, et al. Effects of antrectomy or porta-caval shunting on the histamine-storing endocrine-like cells in oxyntic mucosa of rat stomach. A fluorescence histochemical, electron microscopic and chemical study. J Physiol. 1976;259:785–800
  28. Simonsson M, Eriksson S, Hakanson R, et al. Endocrine cells in the human oxyntic mucosa. A histochemical study. Scand J Gastroenterol. 1988;23:1089–1099
  29. el-Zimaity HM. Jackson FW and Graham DY. Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol. 1997;92:1858–1860
  30. Choudhry U, Boyce HW, Coppola D. Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. Am J Clin Pathol. 1998;110:615–621
  31. Jalving M, Koornstra JJ, Wesseling J, et al. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther. 2006;24:1341–1348
  32. Stolte M, Sticht T, Eidt S, et al. Frequency, location, and age and sex distribution of various types of gastric polyp. Endoscopy. 1994;26:659–665
  33. Archimandritis A, Spiliadis C, Tzivras M, et al. Gastric epithelial polyps: a retrospective endoscopic study of 12974 symptomatic patients. Ital J Gastroenterol. 1996;28:387–390
  34. Cats A, Schenk BE, Bloemena E, et al. Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol. 2000;31:684–690
  35. Stolte M. Fundic gland polyps: a rare, innocuous, and reversible disturbance. Gastroenterology. 1993;105:1590–1591
  36. Abraham SC, Nobukawa B, Giardiello FM, et al. Sporadic fundic gland polyps: common gastric polyps arising through activating mutations in the beta-catenin gene. Am J Pathol. 2001;158:1005–1010
  37. Jalving M, Koornstra JJ, Boersma-van Ek W, et al. Dysplasia in fundic gland polyps is associated with nuclear beta-catenin expression and relatively high cell turnover rates. Scand J Gastroenterol. 2003;38:916–922
  38. Torbenson M, Lee JH, Cruz-Correa M, et al. Sporadic fundic gland polyposis: a clinical, histological, and molecular analysis. Mod Pathol. 2002;15:718–723
  39. Jalving M, Koornstra JJ, Gotz JM, et al. High-grade dysplasia in sporadic fundic gland polyps: a case report and review of the literature. Eur J Gastroenterol Hepatol. 2003;15:1229–1233
  40. Wu TT, Kornacki S, Rashid A, et al. Dysplasia and dysregulation of proliferation in foveolar and surface epithelia of fundic gland polyps from patients with familial adenomatous polyposis. Am J Surg Pathol. 1998;22:293–298
  41. Attard TM, Yardley JH, Cuffari C. Gastric polyps in pediatrics: an 18-year hospital-based analysis. Am J Gastroenterol. 2002;97:298–301
  42. Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion. 1986;35(Suppl. 1):42–55
  43. Laine L, Ahnen D, McClain C, et al. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2000;14:651–668
  44. Gillen D, McColl KE. Problems associated with the clinical use of proton pump inhibitors. Pharmacol Toxicol. 2001;89:281–286
  45. Svendsen JH, Dahl C, Svendsen LB, et al. Gastric cancer risk in achlorhydric patients. A long-term follow-up study. Scand J Gastroenterol. 1986;21:16–20
  46. Carter DC. Cancer after peptic ulcer surgery. Gut. 1987;28:921–923
  47. Freston JW. Clinical significance of hypergastrinaemia: relevance to gastrin monitoring during omeprazole therapy. Digestion. 1992;51(Suppl. 1):102–114
  48. Caygill CP, Hill MJ, Kirkham JS, et al. Mortality from gastric cancer following gastric surgery for peptic ulcer. Lancet. 1986;1:929–931
  49. Moller H, Heseltine E, Vainio H. Working group report on schistosomes, liver flukes and Helicobacter pylori. Int J Cancer. 1995;60:587–589
  50. Correa P, Haenszel W, Cuello C, et al. A model for gastric cancer epidemiology. Lancet. 1975;2:58–60
  51. Sipponen P, Kekki M, Haapakoski J, et al. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer. 1985;35:173–177
  52. Weeks DL, Eskandari S, Scott DR, et al. A H+-gated urea channel: the link between Helicobacter pylori urease and gastric colonization. Science. 2000;287:482–485
  53. Stemmermann GN. Intestinal metaplasia of the stomach. A status report. Cancer. 1994;74:556–564
  54. Fiocca R, Villani L, Luinetti O, et al. Helicobacter colonization and histopathological profile of chronic gastritis in patients with or without dyspepsia, mucosal erosion and peptic ulcer: a morphological approach to the study of ulcerogenesis in man. Virchows Arch A Pathol Anat Histopathol. 1992;420:489–498
  55. Rubin CE. Are there three types of Helicobacter pylori gastritis?. Gastroenterology. 1997;112:2108–2110
  56. Logan RP, Walker MM, Misiewicz JJ, et al. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut. 1995;36:12–16
  57. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol. 1995;90:1401–1406
  58. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996;334:1018–1022
  59. Lundell L, Miettinen P, Myrvold HE, et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology. 1999;117:319–326
  60. Lundell L, Havu N, Miettinen P, et al. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther. 2006;23:639–647
  61. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–789
  62. Sobala GM, Pignatelli B, Schorah CJ, et al. Levels of nitrite, nitrate, N-nitroso compounds, ascorbic acid and total bile acids in gastric juice of patients with and without precancerous conditions of the stomach. Carcinogenesis. 1991;12:193–198
  63. Mowat C, Carswell A, Wirz A, et al. Omeprazole and dietary nitrate independently affect levels of vitamin C and nitrite in gastric juice. Gastroenterology. 1999;116:813–822
  64. Verdu EF, Armstrong D, Fraser R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut. 1995;36:539–543
  65. Recker RR. Calcium absorption and achlorhydria. N Engl J Med. 1985;313:70–73
  66. Bo-Linn GW, Davis GR, Buddrus DJ, et al. An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest. 1984;73:640–647
  67. Chonan O, Takahashi R, Yasui H, et al. Effect of L-lactic acid on calcium absorption in rats fed omeprazole. J Nutr Sci Vitaminol (Tokyo. 1998;44:473–481
  68. O'Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118:778–781
  69. Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr. 1995;14:364–368
  70. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79:76–83
  71. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. Jama. 2006;296:2947–2953
  72. Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. Cmaj. 2008;179:319–326
  73. McNabb PC, Tomasi TB. Host defense mechanisms at mucosal surfaces. Annu Rev Microbiol. 1981;35:477–496
  74. Howden CW, Hunt RH. Relationship between gastric secretion and infection. Gut. 1987;28:96–107
  75. Lewis SJ, Franco S, Young G, et al. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther. 1996;10:557–561
  76. Claessens AA, Heerdink ER, van Eijk JT, et al. Characteristics of diarrhoea in 10,008 users of lansoprazole in daily practice: which co-factors contribute?. Pharmacoepidemiol Drug Saf. 2002;11:703–708
  77. Leufkens H, Claessens A, Heerdink E, et al. A prospective follow-up study of 5669 users of lansoprazole in daily practice. Aliment Pharmacol Ther. 1997;11:887–897
  78. Martin RM, Dunn NR, Freemantle S, et al. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol. 2000;50:366–372
  79. Wilton LV, Key C, Shakir SA. The pharmacovigilance of pantoprazole: the results of postmarketing surveillance on 11 541 patients in England. Drug Saf. 2003;26:121–132
  80. Neal KR, Scott HM, Slack RC, et al. Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study. Bmj. 1996;312:414–415
  81. Garcia Rodriguez LA, Ruigomez A. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk?. Epidemiology. 1997;8:571–574
  82. Doorduyn Y, Van Pelt W, Siezen CL, et al. Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases. Epidemiol Infect. 2008;136:1225–1234
  83. Neal KR, Briji SO, Slack RC, et al. Recent treatment with H2 antagonists and antibiotics and gastric surgery as risk factors for Salmonella infection. Bmj. 1994;308:176
  84. Doorduyn Y, Van Den Brandhof WE, Van Duynhoven YT, et al. Risk factors for Salmonella Enteritidis and Typhimurium (DT104 and non-DT104) infections in The Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in Typhimurium infections. Epidemiol Infect. 2006;134:617–626
  85. Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol. 2007;5:1418–1423
  86. Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect. 2003;54:243–245
  87. Gurian L, Ward TT, Katon RM. Possible foodborne transmission in a case of pseudomembranous colitis due to Clostridium difficile: influence of gastrointestinal secretions on Clostridium difficile infection. Gastroenterology. 1982;83:465–469
  88. Cross AS, Roup B. Role of respiratory assistance devices in endemic nosocomial pneumonia. Am J Med. 1981;70:681–685
  89. Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. Jama. 2004;292:1955–1960
  90. Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med. 2007;167:950–955
  91. Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med. 1994;120:211–215
  92. Force RW, Meeker AD, Cady PS, et al. Ambulatory care increased vitamin B12 requirement associated with chronic acid suppression therapy. Ann Pharmacother. 2003;37:490–493
  93. Dharmarajan TS, Kanagala MR, Murakonda P, et al. Do acid-lowering agents affect vitamin B12 status in older adults?. J Am Med Dir Assoc. 2008;9:162–167
  94. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol. 2004;57:422–428
  95. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355:1834–1836
  96. Shabajee N, Lamb EJ, Sturgess I, et al. Omeprazole and refractory hypomagnesaemia. Bmj. 2008;337:a425
  97. Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors–a review. Neth J Med. 2009;67:169–172
  98. Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf. 2008;69:338–341
  99. Quamme GA. Recent developments in intestinal magnesium absorption. Curr Opin Gastroenterol. 2008;24:230–235
  100. Li M, Jiang J, Yue L. Functional characterization of homo- and heteromeric channel kinases TRPM6 and TRPM7. J Gen Physiol. 2006;127:525–537

PII: S1521-6918(09)00157-7

doi: 10.1016/j.bpg.2009.11.004

Best Practice & Research Clinical Gastroenterology
Volume 24, Issue 2 , Pages 193-201 , April 2010

Article Tools